As of November 4, 2026, Indivior Pharmaceuticals, Inc. is a publicly traded company (Nasdaq: INDV); its largest reported holder is BlackRock, with 14.3% on Schedule 13G/A of January 8, 2026, then Vanguard (6.55%). The largest insider holding is Joseph Ciaffoni, the chief executive and a director, with 790,330 shares (0.67% of shares outstanding), per Form 4 of June 23, 2026 (Schedule 13G/A, January 8, 2026).
Is this your company?
About to sign with, pay or invest in Indivior Pharmaceuticals, Inc.? See the free Snapshot first.
Free to see. No signup.
Is Indivior Pharmaceuticals, Inc. a real, registered company?
- Indivior Pharmaceuticals, Inc. files with the SEC under CIK 1625297 (its SEC filings).
- Its shares are listed under the ticker INDV on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in North Chesterfield, Virginia, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under Indivior Pharmaceuticals, Inc. in our court records and SEC 8-K records (as of 2026-11-04).
- Layoffs: 1 exit or restructuring plan reported on Form 8-K, Item 2.05 (latest filed 2025-10-30).
- Leadership changes: the latest reported is Joseph Ciaffoni, Chief Executive Officer (Form 8-K filed 2026-11-02). Check you are dealing with the people now in charge.
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Millennium (filed 2026-09-30).
Who are Indivior Pharmaceuticals, Inc.'s owners and officers?
Indivior Pharmaceuticals, Inc.: incorporated in Delaware; business address in North Chesterfield, Virginia; industry Pharmaceutical Preparations (Form D, 2026-11-02).
| Report | Holder | Share |
|---|---|---|
| Schedule 13G, 2026-09-30 | Millennium Management LLC | 5.4% |
| Schedule 13D/A, 2026-08-13 | Oaktree Capital Holdings, LLC | 0.76% |
| Schedule 13G/A, 2026-05-15 | Madison Avenue International LP | 3.5% |
| Schedule 13G/A, 2026-05-13 | Fuller & Thaler Asset Management, Inc. | 3.72% |
| Schedule 13G, 2026-04-28 | Vanguard Portfolio Management | 6.55% |
| Schedule 13G, 2026-04-27 | Vanguard Capital Management | 5.35% |
| Schedule 13G, 2026-03-23 | Millennium Management LLC | 3.8% |
| Schedule 13G/A, 2026-02-17 | Madison Avenue International LP | 5% |
| Schedule 13G, 2026-02-17 | Fuller & Thaler Asset Management, Inc. | 5.1% |
| Schedule 13G/A, 2026-02-12 | The Goldman Sachs Group, Inc. | 2.9% |
| Schedule 13G/A, 2026-01-08 | Blackrock, Inc. | 14.3% |
| Schedule 13D/A, 2025-12-30 | Oaktree Capital Holdings, LLC | 5.69% |
Questions about who owns Indivior Pharmaceuticals, Inc.
Who owns Indivior Pharmaceuticals, Inc.?
On this page, 4 holders' latest ownership filings report 5% or more of Indivior Pharmaceuticals, Inc.: Blackrock, Inc. (14.3%, Schedule 13G/A, filed 2026-01-08), Vanguard Portfolio Management (6.55%, Schedule 13G, filed 2026-04-28), Millennium Management LLC (5.4%, Schedule 13G, filed 2026-09-30) and Vanguard Capital Management (5.35%, Schedule 13G, filed 2026-04-27).
Who are the largest shareholders of Indivior Pharmaceuticals, Inc.?
By the share each holder's latest filing reports, the largest holders of Indivior Pharmaceuticals, Inc. on this page are Blackrock, Inc. (14.3%), Vanguard Portfolio Management (6.55%) and Millennium Management LLC (5.4%).
When did Blackrock, Inc. buy into Indivior Pharmaceuticals, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Blackrock, Inc. on this page is the Schedule 13G/A, filed 2026-01-08, reporting 14.3%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 12 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Indivior Pharmaceuticals, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Indivior Pharmaceuticals, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Indivior Pharmaceuticals, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
20 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
| Filed | Person | Role | Change | Effective |
|---|---|---|---|---|
| Form 8-K, 2026-11-02 | Joseph Ciaffoni | Chief Executive Officer | departed |
Which insiders own Indivior Pharmaceuticals, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , the chief executive and a director: 790,330 shares (0.67% of shares outstanding) (Form 4, 2026-06-23).
- , the chief financial officer: 284,751 shares (0.24% of shares outstanding) (Form 4, 2026-06-10).
- , the chief scientific officer: 209,337 shares (0.18% of shares outstanding) (Form 4, 2026-07-13).
- , the chief legal officer: 71,518 shares (0.06% of shares outstanding) (Form 4, 2026-03-05).
- , the chief commercial officer: 31,380 shares (0.03% of shares outstanding) (Form 4, 2026-02-12).
Shares outstanding: 118,035,272 as of 2026-10-09, from the company's latest SEC cover page.
How much has Indivior Pharmaceuticals, Inc. raised?
Acquisitions reported on Form 8-K, Item 2.01: completed an acquisition (2026-11-02).
Red flags found
1 exit or restructuring plan on Form 8-K (latest Form 8-K, 2025-10-30).
Keep reading
More on Indivior Pharmaceuticals, Inc. and the records around it.
Indivior Pharmaceuticals, Inc. elsewhere on the record
- Leadership changes Nov 2026
- 5%+ stake filings Sep 2026
- Layoff notices Oct 2025
Companies that share a holder
- Oaktree Value Opportunities Fund, L.P. also filed stake reports on 4 other companies: TORM plc (Oct 2026), BRC Group Holdings, Inc. (May 2026)
- Madison Avenue International LP also filed stake reports on 11 other companies: Ultragenyx Pharmaceutical Inc. (Oct 2026), Graham Holdings Co (Aug 2026), STAAR SURGICAL CO (Aug 2026)
- Two Seas Capital LP also filed stake reports on 14 other companies: NEKTAR THERAPEUTICS (Sep 2026), Calumet, Inc. (Aug 2026), Quantum Corporation (Aug 2026)
Related pages
LayoffsLeadership changes5%+ holders
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/indivior-pharmaceuticals